

Grasim Industries Limited

Improving outlook in standalone business

Company Update Diversified Sharekhan code: GRASIM

Summary

- We retain our Buy rating on Grasim with a revised PT of Rs. 1,120 as we roll forward our valuation multiple for the standalone business and improve upon the valuation of its subsidiaries, Aditya Birla Capital and Vodafone Idea.
- VSF prices have risen by 27% from the historic lows in August 2020, led by strong demand in the Chinese textile market. The benefit of higher VSF prices is likely to accrue in ensuing quarters.
- Caustic soda prices have started bottoming out during October and November 2020, which along with healthy demand for chlorine to improve upon profitability going ahead.
- Exit from the fertilizer business, partnership with Lubrizol, and increasing capex in the standalone business instill confidence on increasing focus on its core business.

Grasim Industries Limited (Grasim) is expected to benefit from improving standalone operations, aided by improving outlook for both VSF and caustic soda. VSF prices have increased by 27% from their historic low of RMB 8300/tonne in August 2020 to now RMB 10,550, led by strong demand in the Chinese textile market. Operating rates in the VSF industry are now at 75%, while VSF inventory has significantly declined from 45 days in April 2020 to just 14 days in November. Blended realisation for Grasim's VSF segment had declined by 23% y-o-y/-3% q-o-q in Q2FY2021 as VSF prices bottomed out in August 2020 and began to tread higher thereafter. We expect the benefit of higher VSF prices to accrue in the coming quarters for Grasim, owing to firm prices and improved dynamics in the Chinese VSF market. Further, average caustic soda flake and lye prices in Mumbai for October-November 2020 have declined by 7.4% and 4.5%, respectively, compared to Q2FY2021. However, average caustic soda flakes price during October and November 2020 have stabilised with m-o-m improvement of 0.6% and 0.8%, respectively. Hence, we believe caustic soda prices are bottoming out and should improve from here on with demand pick up from textile, paper, and other segments. Further, demand for chlorine is expected to remain healthy, driven by demand from organic intermediaries, agrochemicals, and chlorine product segments. We expect Grasim's chemical segment to benefit from bottoming of caustic soda prices going ahead, which along with its partnership with Lubrizol would aid in improving captive chlorine integration. Grasim's recent exit from the fertiliser business would also increase its focus on the core business. Overall, we see healthy traction in its standalone operations going ahead. The company's revised capex guidance for FY2021 to Rs. 1,852 crore versus earlier guidance of Rs. 1,615 crore reinforces improving business sentiments in both VSF and chemical divisions. We retain our Buy rating on the stock with a revised SOTP-based price target (PT) of Rs. 1,120, as we roll forward our valuation for the standalone business to FY2023, incorporate increased market capitalisation, and lower holding company discount of listed subsidiaries (Aditya Birla Capital and Vodafone Idea).

Valuation - Retain Buy with a revised PT of Rs. 1,120: Grasim is witnessing improving outlook for its standalone business with easing of lockdown restrictions domestically and improving textile demand environment in China. The firming up of VSF prices and bottoming out of caustic soda prices driven by demand from textile and paper industries is expected to benefit Grasim going ahead. Further, the outlook for its key subsidiary, UltraTech, remains healthy with expected demand from government-led infrastructure investments and sustained demand from rural and individual home builders. Hence, we retain our Buy rating on the stock with a revised SOTP-based PT of Rs. 1,120, as we roll forward our valuation for the standalone business to FY2023, incorporate increased market capitalisation, and lower holding company discount of listed subsidiaries (Aditya Birla Capital and Vodafone Idea).

Funding requirement of its group companies and weakness in the standalone business are key risks.

| Valuation (Standalone) | | | | Rs cr |
|------------------------|--------|--------|--------|--------|
| Particulars | FY20 | FY21E | FY22E | FY23E |
| Revenue | 18,609 | 14,526 | 18,136 | 22,227 |
| OPM (%) | 12.4% | 6.9% | 11.0% | 11.8% |
| Adjusted PAT | 1,267 | 390 | 979 | 1,403 |
| % YoY growth | (50.8) | (69.2) | 150.7 | 43.4 |
| Adjusted EPS (Rs.) | 19.3 | 5.9 | 14.9 | 21.3 |
| P/E (x) | 47.3 | 153.2 | 61.1 | 42.6 |
| P/B (x) | 1.6 | 1.5 | 1.4 | 1.4 |
| EV/EBITDA (x) | 17.1 | 36.3 | 18.3 | 14.0 |
| RoNW (%) | 3.4 | 1.0 | 2.3 | 3.3 |
| RoCE (%) | 2.8 | 0.9 | 2.1 | 2.9 |

Source: Company; Sharekhan estimates

Powered by the Sharekhan 3R Research Philosophy **3R MATRIX** Right Sector (RS) Right Quality (RQ) Right Valuation (RV) + Positive = Neutral - Negative What has changed in 3R MATRIX Old New RS ተ RQ RV

| Reco/View | Change | |
|-------------------------|-------------------|--|
| Reco: Buy | \leftrightarrow | |
| CMP: Rs. 910 | | |
| Price Target: Rs. 1,120 | 1 | |
| ↑ Upgrade ↔ Maintain | ↓ Downgrade | |


Company details

| Market cap: | Rs. 59,875 cr |
|-------------------------------|---------------|
| 52-week high/low: | Rs. 924/380 |
| NSE volume: (No of shares) | 27.8 lakh |
| BSE code: | 500300 |
| NSE code: | GRASIM |
| Free float: (No of shares) | 38.9 cr |

Shareholding (%)

| Promoters | 40.9 |
|-----------|------|
| FII | 12.6 |
| DII | 20.5 |
| Others | 26.1 |

Price chart



Price performance


| (%) | 1m | 3m | 6m | 12m |
|-------------------------------|------|------|------|------|
| Absolute | 16.1 | 28.8 | 50.3 | 15.8 |
| Relative to Sensex | 6.2 | 12.5 | 19.0 | 6.6 |
| Sharekhan Research, Bloomberg | | | | |

December 03, 2020

Firm VSF prices and improved Chinese VSF market to benefit in the coming quarters


VSF prices increased by 27% from their historic low of RMB 8300/tonne in August 2020 to now RMB 10,550, led by strong demand in the Chinese textile market. Operating rates in the VSF industry are now at 75%, while VSF inventory has significantly declined from 45 days in April 2020 to just 14 days in November. Blended realisation for Grasim's VSF segment had declined by 23% y-o-y/-3% q-o-q in Q2FY2021, as VSF prices bottomed out in August 2020 and began to tread higher thereafter. We expect the benefit of higher VSF prices to accrue in the coming quarters for Grasim owing to firm prices and improved dynamics in the Chinese VSF market.

Viscose/Cotton/Pulp price trend



Source: Industry; Sharekhan Research

VSF price trend in China



Source: Industry; Sharekhan Research


December 03, 2020 2



Caustic soda prices bottoming out


The average caustic soda flake and lye prices in Mumbai for October-November 2020 has declined by 7.4% and 4.5%, respectively, compared to Q2FY2021. However, average caustic soda flakes price during October and November 2020 has stabilized with m-o-m improvement of 0.6% and 0.8%, respectively. Hence, we believe caustic soda prices are bottoming out and should improve from here on, with demand pick up from textile, paper, and other segments. Further, demand for chlorine is expected to remain healthy, driven by demand from organic intermediaries, agrochemicals, and chlorine product segments. We expect Grasim's chemical segment to benefit from bottoming of caustic soda prices going ahead.

Caustic soda flakes price in Mumbai trend



Source: Industry; Sharekhan Research

Caustic soda lye price in Mumbai trend




Source: Industry; Sharekhan Research

December 03, 2020 3

Stock Update Sharekhan


Financials in charts

VSF/VFY sales volume trend




Source: Company, Sharekhan Research

VSF/VFY realisation trend




Source: Company, Sharekhan Research

VSF EBITDA trend




Source: Company, Sharekhan Research

Chemical sales volume trend




Source: Company, Sharekhan Research

Chemical EBITDA margin trend



Source: Company, Sharekhan Research

Standalone Leverage trend



Source: Company, Sharekhan Research

4 December 03, 2020



Outlook and Valuation

Sector View – Improving outlook of the standalone business and healthy outlook of key subsidiary

Grasim is witnessing improving outlook for its standalone business with easing of lockdown restrictions domestically and improving textile demand environment in China. The firming up of VSF prices and bottoming out of caustic soda prices driven by demand from textile and paper industries is expected to benefit Grasim going ahead. Further, the outlook for its key subsidiary, UltraTech, remains healthy with expected demand from government-led infrastructure investments and sustained demand from rural and individual home builders. Hence, overall Grasim's standalone operations are seeing improving traction, while the outlook of its key subsidiary, UltraTech, remains positive.


Company Outlook – Improved business environment and clarity on capital allocation

The company is benefitting from improved domestic demand environment for its key standalone businesses, led by a pickup in demand from end-user industries. The same has led to increased capex expenditure and expansion in both the verticals. Further, management's clarity on capital allocation with first priority to be given to the standalone business and nil future investment for listed telecom investment removes a key hangover on the stock. Hence, overall, improvement in standalone the business along with clarity on capital allocation is expected to improve upon its earnings and valuation.

■ Valuation – Retain Buy with a revised PT of Rs. 1,120

Grasim is witnessing improving outlook for its standalone business with easing of lockdown restrictions domestically and improving textile demand environment in China. The firming up of VSF prices and bottoming out of caustic soda prices driven by demand from textile and paper industries is expected to benefit Grasim going ahead. Further, the outlook for its key subsidiary, UltraTech, remains healthy with expected demand from government-led infrastructure investments and sustained demand from rural and individual home builders. Hence, we retain our Buy rating on the stock with a revised SOTP-based PT of Rs. 1,120 as, we roll forward our valuation for the standalone business to FY2023, incorporate increased market capitalisation, and lower holding company discount of listed subsidiaries (Aditya Birla Capital and Vodafone Idea).





Source: Sharekhan Research

December 03, 2020 5



About company

Grasim is the flagship company of Aditya Birla Group. The company started as a textiles manufacturer in India in 1947. The cement business was started in 1985 with capacity of 0.5 MTPA. Aditya Birla Nuvo Limited, an Aditya Birla Group Company, was merged with Grasim w.e.f. July 1, 2017. Subsequently, the financial services business was demerged from the merged entity and was listed on the bourses as Aditya Birla Capital Limited (ABCL) on September 1, 2017. Currently, it is a leading global player in VSF, and is the largest chemicals (Chlor-Alkalis), cement, and diversified financial services (NBFC, Asset Management, and Life Insurance) player in India.

Investment theme

Grasim is witnessing improving outlook for its standalone business with easing of lockdown restrictions domestically and improving textile demand environment in China. The firming up of VSF prices and bottoming out of caustic soda prices driven by demand from textile and paper industries is expected to benefit Grasim going ahead. Further, the outlook for its key subsidiary, UltraTech, remains healthy with expected demand from government-led infrastructure investments and sustained demand from rural and individual home builders.

Key Risks

- Funding requirements of its other listed entities.
- Pressure on VSF and chemical division's demand and/or realisations affects profitability negatively.
- Higher holding company discounts for any of its other business such as telecom, cement, and financial services.

Additional Data

Key management personnel

| Mr. Kumar Mangalam Birla | Chairman |
|--------------------------|-------------------------|
| Mr. Dilip Gaur | Managing Director |
| Mr. Ashish Adukia | Chief Financial Officer |
| Mrs. Hutokshi R Wadia | Company Secretary |

Source: Company Website

Top 10 shareholders

| Sr. No. | Holder Name | Holding (%) |
|---------|------------------------------------|-------------|
| 1 | Birla Group Holdings Pvt Ltd | 19 |
| 2 | Life Insurance Corp of India | 11.29 |
| 3 | IGH Holdings Pvt Ltd | 5.77 |
| 4 | Hindalco Industries Ltd | 4.29 |
| 5 | Umang Commercial Co Ltd | 4.07 |
| 6 | Standard Life Aberdeen PLC | 3.98 |
| 7 | Pilani Investment & Industries Cor | 3.76 |
| 8 | ICICI Prudential Asset Management | 1.93 |
| 9 | Vanguard Group Inc/The | 1.73 |
| 10 | ICICI Prudential Life Insurance Co | 1.4 |

Source: Bloomberg

Sharekhan Limited, its analyst or dependant(s) of the analyst might be holding or having a position in the companies mentioned in the article.

December 03, 2020 6

Understanding the Sharekhan 3R Matrix

| Right Sector | |
|-----------------|--|
| Positive | Strong industry fundamentals (favorable demand-supply scenario, consistent industry growth), increasing investments, higher entry barrier, and favorable government policies |
| Neutral | Stagnancy in the industry growth due to macro factors and lower incremental investments by Government/private companies |
| Negative | Unable to recover from low in the stable economic environment, adverse government policies affecting the business fundamentals and global challenges (currency headwinds and unfavorable policies implemented by global industrial institutions) and any significant increase in commodity prices affecting profitability. |
| Right Quality | |
| Positive | Sector leader, Strong management bandwidth, Strong financial track-record, Healthy Balance sheet/cash flows, differentiated product/service portfolio and Good corporate governance. |
| Neutral | Macro slowdown affecting near term growth profile, Untoward events such as natural calamities resulting in near term uncertainty, Company specific events such as factory shutdown, lack of positive triggers/events in near term, raw material price movement turning unfavourable |
| Negative | Weakening growth trend led by led by external/internal factors, reshuffling of key management personal, questionable corporate governance, high commodity prices/weak realisation environment resulting in margin pressure and detoriating balance sheet |
| Right Valuation | |
| Positive | Strong earnings growth expectation and improving return ratios but valuations are trading at discount to industry leaders/historical average multiples, Expansion in valuation multiple due to expected outperformance amongst its peers and Industry up-cycle with conducive business environment. |
| Neutral | Trading at par to historical valuations and having limited scope of expansion in valuation multiples. |
| Negative | Trading at premium valuations but earnings outlook are weak; Emergence of roadblocks such as corporate governance issue, adverse government policies and bleak global macro environment etc warranting for lower than historical valuation multiple. |

Source: Sharekhan Research



Know more about our products and services

For Private Circulation only

Disclaimer: This document has been prepared by Sharekhan Ltd. (SHAREKHAN) and is intended for use only by the person or entity to which it is addressed to. This Document may contain confidential and/or privileged material and is not for any type of circulation and any review, retransmission, or any other use is strictly prohibited. This Document is subject to changes without prior notice. This document does not constitute an offer to sell or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. Though disseminated to all customers who are due to receive the same, not all customers may receive this report at the same time. SHAREKHAN will not treat recipients as customers by virtue of their receiving this report.

The information contained herein is obtained from publicly available data or other sources believed to be reliable and SHAREKHAN has not independently verified the accuracy and completeness of the said data and hence it should not be relied upon as such. While we would endeavour to update the information herein on reasonable basis, SHAREKHAN, its subsidiaries and associated companies, their directors and employees ("SHAREKHAN and affiliates") are under no obligation to update or keep the information current. Also, there may be regulatory, compliance, or other reasons that may prevent SHAREKHAN and affiliates from doing so. This document is prepared for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. Recipients of this report should also be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The user assumes the entire risk of any use made of this information. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. We do not undertake to advise you as to any change of our views. Affiliates of Sharekhan may have issued other reports that are inconsistent with and reach different conclusions from the information presented in this report.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SHAREKHAN and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

The analyst certifies that the analyst has not dealt or traded directly or indirectly in securities of the company and that all of the views expressed in this document accurately reflect his or her personal views about the subject company or companies and its or their securities and do not necessarily reflect those of SHAREKHAN. The analyst further certifies that neither he or its associates or his relatives has any direct or indirect financial interest nor have actual or beneficial ownership of 1% or more in the securities of the company at the end of the month immediately preceding the date of publication of the research report nor have any material conflict of interest nor has served as officer, director or employee or engaged in market making activity of the company. Further, the analyst has also not been a part of the team which has managed or co-managed the public offerings of the company and no part of the analyst's compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this document. Sharekhan Limited or its associates or analysts have not received any compensation for investment banking, merchant banking, brokerage services or any compensation or other benefits from the subject company or from third party in the past twelve months in connection with the research report.

Either SHAREKHAN or its affiliates or its directors or employees / representatives / clients or their relatives may have position(s), make market, act as principal or engage in transactions of purchase or sell of securities, from time to time or may be materially interested in any of the securities or related securities referred to in this report and they may have used the information set forth herein before publication. SHAREKHAN may from time to time solicit from, or perform investment banking, or other services for, any company mentioned herein. Without limiting any of the foregoing, in no event shall SHAREKHAN, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind.

Compliance Officer: Mr. Joby John Meledan; Tel: 022-61150000; email id: compliance@sharekhan.com; For any queries or grievances kindly email igc@sharekhan.com or contact: myaccount@sharekhan.com

Registered Office: Sharekhan Limited, 10th Floor, Beta Building, Lodha iThink Techno Campus, Off. JVLR, Opp. Kanjurmarg Railway Station, Kanjurmarg (East), Mumbai – 400042, Maharashtra. Tel: 022 - 61150000. Sharekhan Ltd.: SEBI Regn. Nos.: BSE / NSE / MSEI (CASH / F&O / CD) / MCX - Commodity: INZ000171337; DP: NSDL/CDSL-IN-DP-365-2018; PMS: INP000005786; Mutual Fund: ARN 20669; Research Analyst: INH000006183;

Disclaimer: Client should read the Risk Disclosure Document issued by SEBI & relevant exchanges and the T&C on www.sharekhan.com; Investment in securities market are subject to market risks, read all the related documents carefully before investing.